NeuroMetrix Beheer

Beheer criteriumcontroles 4/4

De CEO NeuroMetrix is Shai Gozani, benoemd in Jun1996, heeft een ambtstermijn van 28.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 475.85K, bestaande uit 93.3% salaris en 6.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.65% van de aandelen van het bedrijf, ter waarde $ 50.36K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 11.3 jaar en 13.7 jaar.

Belangrijke informatie

Shai Gozani

Algemeen directeur

US$475.9k

Totale compensatie

Percentage CEO-salaris	93.3%
Dienstverband CEO	28.4yrs
Eigendom CEO	0.7%
Management gemiddelde ambtstermijn	11.3yrs
Gemiddelde ambtstermijn bestuur	13.7yrs

Recente managementupdates

Recent updates

NeuroMetrix reports Q3 results

Oct 20

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Sep 23

NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

Jul 21

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

May 11

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

Jan 19

NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation

Sep 09

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Jul 21

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

Jan 27

Analyse CEO-vergoeding

Hoe is Shai Gozani's beloning veranderd ten opzichte van NeuroMetrix's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$8m
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$476k	US$444k	-US$7m
Sep 30 2023	n/a	n/a	-US$6m
Jun 30 2023	n/a	n/a	-US$5m
Mar 31 2023	n/a	n/a	-US$5m
Dec 31 2022	US$645k	US$415k	-US$4m
Sep 30 2022	n/a	n/a	-US$5m
Jun 30 2022	n/a	n/a	-US$4m
Mar 31 2022	n/a	n/a	-US$3m
Dec 31 2021	US$558k	US$415k	-US$2m
Sep 30 2021	n/a	n/a	-US$2m
Jun 30 2021	n/a	n/a	-US$1m
Mar 31 2021	n/a	n/a	-US$1m
Dec 31 2020	US$181k	US$181k	-US$2m
Sep 30 2020	n/a	n/a	-US$3m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$775k	US$422k	-US$4m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	-US$3m
Mar 31 2019	n/a	n/a	US$908k
Dec 31 2018	US$478k	US$415k	US$24k
Sep 30 2018	n/a	n/a	-US$54k
Jun 30 2018	n/a	n/a	-US$7m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$610k	US$415k	-US$20m

Compensatie versus markt: De totale vergoeding ($USD 475.85K ) Shai } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 656.26K ).

Compensatie versus inkomsten: De vergoeding van Shai is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Shai Gozani (59 yo)

28.4yrs

Tenure

US$475,850

Compensatie

Dr. Shai N. Gozani, M.D., Ph D., founded Neurometrix Inc. in 1996 and has been its President since 2002 and Chief Executive Officer since 1997 and its Secretary July 2008. He has been the Chairman of the B...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Shai Gozani	Founder	28.4yrs	US$475.85k	0.65% $ 50.4k
Thomas Higgins	Senior VP	15.2yrs	US$371.60k	0.50% $ 38.7k
Xuan Kong	Chief Data Scientist	7.4yrs	geen gegevens	geen gegevens
Susan Bell	Senior Vice President of Population Health & Value Based Care	3.1yrs	geen gegevens	geen gegevens

11.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van NURO is doorgewinterd en ervaren (gemiddelde ambtstermijn van 11.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Shai Gozani	Founder	28.4yrs	US$475.85k	0.65% $ 50.4k
Nancy Katz	Independent Director	13.9yrs	US$105.00k	0.38% $ 29.0k
David Goodman	Independent Director	20.4yrs	US$110.00k	0.38% $ 29.0k
Arthur Vinik	Member of Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
Andrew Boulton	Member of the Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
David Van Avermaete	Independent Director	11.2yrs	US$105.00k	0.38% $ 29.0k
Neil Brooks	Member of the Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
David Armstrong	Member of the Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
Solomon Tesfaye	Member of the Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
Dan Ziegler	Member of the Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
Bruce Perkins	Member of the Scientific Advisory Board	13.7yrs	geen gegevens	geen gegevens
Jiro Nakamura	Member of Scientific Advisory Board	10.8yrs	geen gegevens	geen gegevens

13.7yrs

Gemiddelde duur

66.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NURO zijn ervaren en ervaren (gemiddelde ambtstermijn van 13.7 jaar).

NeuroMetrix Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

NeuroMetrix, Inc., Annual General Meeting, Apr 30, 2024

Insufficient new directors

Neurometrix, Inc. Appoints Jonathan Breck Harmel as National Director of Sales

NeuroMetrix, Inc. Appoints Brad Fluegel to Its Board of Directors, Effective July 1, 2022

Insufficient new directors

Senior VP recently sold US$528k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.75 loss per share (vs US$1.66 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.75 loss per share (vs US$1.56 loss in 2Q 2023)

NeuroMetrix, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$1.67 loss per share (vs US$1.64 loss in 1Q 2023)

NeuroMetrix, Inc. has completed a Follow-on Equity Offering in the amount of $0.692831 million.

NeuroMetrix, Inc., Annual General Meeting, Apr 30, 2024

NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

New major risk - Shareholder dilution

RS Fund Discloses its Views on NeuroMetrix

Full year 2023 earnings released: US$6.08 loss per share (vs US$4.96 loss in FY 2022)

NeuroMetrix, Inc. to Report Q4, 2023 Results on Feb 22, 2024

NeuroMetrix, Inc. Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy

Third quarter 2023 earnings released: US$0.21 loss per share (vs US$0.23 loss in 3Q 2022)

New minor risk - Share price stability

NeuroMetrix, Inc. to Report Q3, 2023 Results on Oct 26, 2023

NeuroMetrix Receives Non-Compliance Notice From Nasdaq

NeuroMetrix, Inc. to Report Q2, 2023 Results on Jul 27, 2023

NeuroMetrix, Inc. Announces Sales Force Expansion for Quell Fibromyalgia

NeuroMetrix, Inc. Announces Presentation of New Clinical Data At the Diabetes UK Meeting

NeuroMetrix, Inc. Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy

First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.14 loss in 1Q 2022)

Full year 2022 earnings released: US$0.62 loss per share (vs US$0.45 loss in FY 2021)

NeuroMetrix, Inc. to Report Q4, 2022 Results on Feb 23, 2023

NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

Insufficient new directors

NeuroMetrix, Inc. to Introduce Quell Fibromyalgia At the American College of Rheumatology 2022 Annual Meeting

NeuroMetrix, Inc. Announces Strategic Launch of Quell Fibromyalgia

Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.12 loss in 3Q 2021)

NeuroMetrix reports Q3 results

NeuroMetrix, Inc. to Report Q3, 2022 Results on Oct 20, 2022

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Neurometrix, Inc. Appoints Jonathan Breck Harmel as National Director of Sales

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.13 loss in 2Q 2021)

NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

NeuroMetrix, Inc. to Report Q2, 2022 Results on Jul 21, 2022

NeuroMetrix, Inc. Appoints Brad Fluegel to Its Board of Directors, Effective July 1, 2022

NeuroMetrix, Inc. Reports Quell(R) Wearable Neuromodulation Device Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Insufficient new directors

NeuroMetrix, Inc. to Report Q1, 2022 Results on Apr 26, 2022

NeuroMetrix, Inc. Reports That Quell® Wearable Neuromodulator to Be Evaluated in Post-Acute Covid-19 Syndrome

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.068 loss in 3Q 2020)

NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation

Senior VP recently sold US$528k worth of stock

Senior VP recently sold US$271k worth of stock

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.28 loss in 2Q 2020)

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

NeuroMetrix, Inc. Announces Quell Technology

NeuroMetrix Announces Top-Line Results from a Randomized Controlled Trial of Quell for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences

First quarter 2021 earnings released: US$0.016 loss per share (vs US$0.45 loss in 1Q 2020)

NeuroMetrix, Inc., Annual General Meeting, Apr 27, 2021

Full year 2020 earnings released: US$0.55 loss per share (vs US$3.90 loss in FY 2019)

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

NeuroMetrix, Inc. to Report Q4, 2020 Results on Jan 28, 2021

New 90-day high: US$3.76

New 90-day high: US$3.05

New 90-day high: US$1.86

Third quarter earnings released

NeuroMetrix, Inc. to Report Q3, 2020 Results on Oct 22, 2020

NeuroMetrix, Inc. Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-The-Counter Pain Relief Device

New 90-day low - US$1.72

NeuroMetrix, Inc. to Report Q2, 2020 Results on Jul 23, 2020

Analyse CEO-vergoeding

CEO

Tenure